BioSpace News Archive

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, provides an update on the ongoing development of its product candidates, eftilagimod alpha and IMP761.

Agropur inc. and OptiBiotix® have partnered to bring SlimBiome®, a revolutionary ingredient that transforms the traditional approach to weight loss, to the North American market.

DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the publication of previously released interim clinical data in the February 2020 issue of peer-reviewed journal, Glioma.

Trisha Anest, MD, MPH, FACEP, Director of the Emergency Department at Bon Secours Mary Immaculate Hospital, was recently selected as one of three 2019 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed the hospital’s Emergency Medicine program since February 2016.

Thomas Wulf, MD, Director of the Emergency Department at Eastern New Mexico Medical Center, was recently selected as one of three 2019 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed the hospital’s Emergency Medicine program since 2011.

Frank Kelley, MD, Director of Hospital Medicine at University Hospitals Portage Medical Center, was recently selected as one of three 2019 Facility Medical Directors of the Year by Alteon Health, the industry-leading national medical group that has managed Portage’s Hospitalist program since 2006.

Respondents Want Confidence in Data Privacy, Have Some Knowledge Gaps

TOMI Environmental Solutions, Inc.®, is a global company specializing in disinfection and decontamination, utilizing its premier Binary Ionization Technology platform through its SteraMist products - a hydrogen peroxide-based mist and fog composed of ionized Hydrogen Peroxide.

COCRYSTAL PHARMA, INC. announced the pricing of a registered direct offering with gross proceeds to the Company expected to be approximately $2.2 million before deducting placement agent commissions and expenses.

Coalition of State Rheumatology Organizations (CSRO) physicians are voicing concern for patients who will fall victim of a dangerous new prescription policy.